7 results on '"Herbert, Andrew S."'
Search Results
2. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein
- Author
-
Keck, Zhen-Yong, primary, Enterlein, Sven G., additional, Howell, Katie A., additional, Vu, Hong, additional, Shulenin, Sergey, additional, Warfield, Kelly L., additional, Froude, Jeffrey W., additional, Araghi, Nazli, additional, Douglas, Robin, additional, Biggins, Julia, additional, Lear-Rooney, Calli M., additional, Wirchnianski, Ariel S., additional, Lau, Patrick, additional, Wang, Yong, additional, Herbert, Andrew S., additional, Dye, John M., additional, Glass, Pamela J., additional, Holtsberg, Frederick W., additional, Foung, Steven K. H., additional, and Aman, M. Javad, additional
- Published
- 2016
- Full Text
- View/download PDF
3. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses
- Author
-
Holtsberg, Frederick W., primary, Shulenin, Sergey, additional, Vu, Hong, additional, Howell, Katie A., additional, Patel, Sonal J., additional, Gunn, Bronwyn, additional, Karim, Marcus, additional, Lai, Jonathan R., additional, Frei, Julia C., additional, Nyakatura, Elisabeth K., additional, Zeitlin, Larry, additional, Douglas, Robin, additional, Fusco, Marnie L., additional, Froude, Jeffrey W., additional, Saphire, Erica Ollmann, additional, Herbert, Andrew S., additional, Wirchnianski, Ariel S., additional, Lear-Rooney, Calli M., additional, Alter, Galit, additional, Dye, John M., additional, Glass, Pamela J., additional, Warfield, Kelly L., additional, and Aman, M. Javad, additional
- Published
- 2016
- Full Text
- View/download PDF
4. Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Protects Nonhuman Primates from Intramuscular and Aerosol Challenge with Ebolavirus
- Author
-
Herbert, Andrew S., primary, Kuehne, Ana I., additional, Barth, James F., additional, Ortiz, Ramon A., additional, Nichols, Donald K., additional, Zak, Samantha E., additional, Stonier, Spencer W., additional, Muhammad, Majidat A., additional, Bakken, Russell R., additional, Prugar, Laura I., additional, Olinger, Gene G., additional, Groebner, Jennifer L., additional, Lee, John S., additional, Pratt, William D., additional, Custer, Max, additional, Kamrud, Kurt I., additional, Smith, Jonathan F., additional, Hart, Mary Kate, additional, and Dye, John M., additional
- Published
- 2013
- Full Text
- View/download PDF
5. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
- Author
-
Zhen-Yong Keck, Enterlein, Sven G., Howell, Katie A., Vu, Hong, Shulenin, Sergey, Warfield, Kelly L., Froude, Jeffrey W., Araghi, Nazli, Douglas, Robin, Biggins, Julia, Lear-Rooney, Calli M., Wirchnianski, Ariel S., Lau, Patrick, Yong Wang, Herbert, Andrew S., Dye, John M., Glass, Pamela J., Holtsberg, Frederick W., Foung, Steven K. H., and Aman, M. Javad
- Subjects
- *
FILOVIRIDAE , *IMMUNOTHERAPY , *MONOCLONAL antibodies , *IMMUNOGLOBULINS - Abstract
Filoviruses cause highly lethal viral hemorrhagic fever in humans and nonhuman primates. Current immunotherapeutic options for filoviruses are mostly specific to Ebola virus (EBOV), although other members of Filoviridae such as Sudan virus (SUDV), Bundibugyo virus (BDBV), and Marburg virus (MARV) have also caused sizeable human outbreaks. Here we report a set of pan-ebolavirus and pan-filovirus monoclonal antibodies (MAbs) derived from cynomolgus macaques immunized repeatedly with a mixture of engineered glycoproteins (GPs) and virus-like particles (VLPs) for three different filovirus species. The antibodies recognize novel neutralizing and nonneutralizing epitopes on the filovirus glycoprotein, including conserved conformational epitopes within the core regions of the GP1 subunit and a novel linear epitope within the glycan cap. We further report the first filovirus antibody binding to a highly conserved epitope within the fusion loop of ebolavirus and marburgvirus species. One of the antibodies binding to the core GP1 region of all ebolavirus species and with lower affinity to MARV GP cross neutralized both SUDV and EBOV, the most divergent ebolavirus species. In a mouse model of EBOV infection, this antibody provided 100% protection when administered in two doses and partial, but significant, protection when given once at the peak of viremia 3 days postinfection. Furthermore, we describe novel cocktails of antibodies with enhanced protective efficacy compared to individual MAbs. In summary, the present work describes multiple novel, cross-reactive filovirus epitopes and innovative combination concepts that challenge the current therapeutic models. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
- Author
-
Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SK, and Aman MJ
- Subjects
- Animals, Antibodies, Monoclonal isolation & purification, Antibodies, Monoclonal therapeutic use, Antibodies, Neutralizing immunology, Antibodies, Neutralizing isolation & purification, Antibodies, Neutralizing therapeutic use, Antibodies, Viral isolation & purification, Antibodies, Viral therapeutic use, Cross Reactions, Disease Models, Animal, Female, Immunization, Passive, Macaca, Mice, Inbred BALB C, Survival Analysis, Treatment Outcome, Antibodies, Monoclonal immunology, Antibodies, Viral immunology, Epitopes immunology, Filoviridae immunology, Glycoproteins immunology, Hemorrhagic Fever, Ebola prevention & control, Viral Proteins immunology
- Abstract
Unlabelled: Filoviruses cause highly lethal viral hemorrhagic fever in humans and nonhuman primates. Current immunotherapeutic options for filoviruses are mostly specific to Ebola virus (EBOV), although other members of Filoviridae such as Sudan virus (SUDV), Bundibugyo virus (BDBV), and Marburg virus (MARV) have also caused sizeable human outbreaks. Here we report a set of pan-ebolavirus and pan-filovirus monoclonal antibodies (MAbs) derived from cynomolgus macaques immunized repeatedly with a mixture of engineered glycoproteins (GPs) and virus-like particles (VLPs) for three different filovirus species. The antibodies recognize novel neutralizing and nonneutralizing epitopes on the filovirus glycoprotein, including conserved conformational epitopes within the core regions of the GP1 subunit and a novel linear epitope within the glycan cap. We further report the first filovirus antibody binding to a highly conserved epitope within the fusion loop of ebolavirus and marburgvirus species. One of the antibodies binding to the core GP1 region of all ebolavirus species and with lower affinity to MARV GP cross neutralized both SUDV and EBOV, the most divergent ebolavirus species. In a mouse model of EBOV infection, this antibody provided 100% protection when administered in two doses and partial, but significant, protection when given once at the peak of viremia 3 days postinfection. Furthermore, we describe novel cocktails of antibodies with enhanced protective efficacy compared to individual MAbs. In summary, the present work describes multiple novel, cross-reactive filovirus epitopes and innovative combination concepts that challenge the current therapeutic models., Importance: Filoviruses are among the most deadly human pathogens. The 2014-2015 outbreak of Ebola virus disease (EVD) led to more than 27,000 cases and 11,000 fatalities. While there are five species of Ebolavirus and several strains of marburgvirus, the current immunotherapeutics primarily target Ebola virus. Since the nature of future outbreaks cannot be predicted, there is an urgent need for therapeutics with broad protective efficacy against multiple filoviruses. Here we describe a set of monoclonal antibodies cross-reactive with multiple filovirus species. These antibodies target novel conserved epitopes within the envelope glycoprotein and exhibit protective efficacy in mice. We further present novel concepts for combination of cross-reactive antibodies against multiple epitopes that show enhanced efficacy compared to monotherapy and provide complete protection in mice. These findings set the stage for further evaluation of these antibodies in nonhuman primates and development of effective pan-filovirus immunotherapeutics for use in future outbreaks., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
7. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
- Author
-
Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, and Aman MJ
- Subjects
- Animals, Antibodies, Monoclonal administration & dosage, Antibodies, Neutralizing administration & dosage, Antibodies, Neutralizing immunology, Antibodies, Neutralizing isolation & purification, Antibodies, Viral administration & dosage, Cross Protection, Disease Models, Animal, Epitopes immunology, Female, Mice, Inbred BALB C, Treatment Outcome, Antibodies, Monoclonal immunology, Antibodies, Monoclonal isolation & purification, Antibodies, Viral immunology, Antibodies, Viral isolation & purification, Filoviridae immunology, Hemorrhagic Fever, Ebola prevention & control, Immunization, Passive
- Abstract
Unlabelled: The unprecedented 2014-2015 Ebola virus disease (EVD) outbreak in West Africa has highlighted the need for effective therapeutics against filoviruses. Monoclonal antibody (MAb) cocktails have shown great potential as EVD therapeutics; however, the existing protective MAbs are virus species specific. Here we report the development of pan-ebolavirus and pan-filovirus antibodies generated by repeated immunization of mice with filovirus glycoproteins engineered to drive the B cell responses toward conserved epitopes. Multiple pan-ebolavirus antibodies were identified that react to the Ebola, Sudan, Bundibugyo, and Reston viruses. A pan-filovirus antibody that was reactive to the receptor binding regions of all filovirus glycoproteins was also identified. Significant postexposure efficacy of several MAbs, including a novel antibody cocktail, was demonstrated. For the first time, we report cross-neutralization and in vivo protection against two highly divergent filovirus species, i.e., Ebola virus and Sudan virus, with a single antibody. Competition studies indicate that this antibody targets a previously unrecognized conserved neutralizing epitope that involves the glycan cap. Mechanistic studies indicated that, besides neutralization, innate immune cell effector functions may play a role in the antiviral activity of the antibodies. Our findings further suggest critical novel epitopes that can be utilized to design effective cocktails for broad protection against multiple filovirus species., Importance: Filoviruses represent a major public health threat in Africa and an emerging global concern. Largely driven by the U.S. biodefense funding programs and reinforced by the 2014 outbreaks, current immunotherapeutics are primarily focused on a single filovirus species called Ebola virus (EBOV) (formerly Zaire Ebola virus). However, other filoviruses including Sudan, Bundibugyo, and Marburg viruses have caused human outbreaks with mortality rates as high as 90%. Thus, cross-protective immunotherapeutics are urgently needed. Here, we describe monoclonal antibodies with cross-reactivity to several filoviruses, including the first report of a cross-neutralizing antibody that exhibits protection against Ebola virus and Sudan virus in mice. Our results further describe a novel combination of antibodies with enhanced protective efficacy. These results form a basis for further development of effective immunotherapeutics against filoviruses for human use. Understanding the cross-protective epitopes are also important for rational design of pan-ebolavirus and pan-filovirus vaccines., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.